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Huntington’s disease (HD) is an inherited, progressive neurological
disorder that is caused by a CAGpolyglutamine repeat expansion
and for which there is no effective therapy. Recent evidence
indicates that transcriptional dysregulation may contribute to the
molecular pathogenesis of this disease. Supporting this view,
administration of histone deacetylase (HDAC) inhibitors has been
shown to rescue lethality and photoreceptor neurodegeneration in
a Drosophila model of polyglutamine disease. To further explore
the therapeutic potential of HDAC inhibitors, we have conducted
preclinical trials with suberoylanilide hydroxamic acid (SAHA), a
potent HDAC inhibitor, in the R62 HD mouse model. We show that
SAHA crosses the blood–brain barrier and increases histone acet-
ylation in the brain. We found that SAHA could be administered
orally in drinking water when complexed with cyclodextrins.
SAHA dramatically improved the motor impairment in R62 mice,
clearly validating the pursuit of this class of compounds as HD
therapeutics.
Huntington’s disease (HD) is an inherited progressive neu-rological disorder caused by a CAGpolyglutamine (polyQ)
expansion and is associated with selective cell death and the
deposition of polyQ aggregates in the brain (1). Recent studies
suggest that transcriptional dysregulation might play a role in
HD pathogenesis (2–4) by decreasing several functions including
histone acetyltransferase and Sp1 and TAFII130 activity (5–13).
Although the molecular basis of transcriptional dysfunction in
HD requires further dissection, transcriptional repression is the
predominant result of dysregulation.
Histone deacetylases (HDACs) work in concert with histone
acetyl transferases to modify chromatin and regulate transcrip-
tion (14). HDAC inhibitors such as trichostatin A and suberoy-
lanilide hydroxamic acid (SAHA) have been shown to act
selectively on gene expression and are potent inducers of growth
arrest, differentiation, andor apoptotic cell death of trans-
formed cells in vitro and in vivo (15–18). Recent studies in cell
culture, yeast, and Drosophila models of polyQ disease have
indicated that HDAC inhibitors might provide a useful class of
agents to ameliorate the transcriptional changes in HD (9–11).
For example, alleviation of transcriptional repression in Dro-
sophila models either by genetic reduction of Sin3A corepressor
activity or through administration of HDAC inhibitors
was shown to rescue lethality and photoreceptor neurodegenera-
tion (11).
Therapeutic trials in humans are challenging, because of the
late onset, variability, and slow progression of HD. Therefore,
before testing novel therapeutics in clinical trials, compounds
must be rigorously and extensively evaluated in genetic HD
mouse models, a wide range of which are now available (19). The
R62 line (20, 21) has been used the most extensively for
preclinical trials (22–25). The early onset of impairment (5–6
weeks), rapid progression of the disease (severely impaired at
12–14 weeks), and reproducibility of the phenotype makes it
particularly suitable for this type of study.
Here we ask whether the beneficial effects of HDAC inhibi-
tors in Drosophila models of polyQ disease can be reproduced in
preclinical mouse trials. We show that SAHA can cross the
blood–brain barrier and demonstrate bioactivity in brain tissue.
SAHA has an effective concentration of 2.5 M and is
relatively insoluble in aqueous solution. We show that when
complexed with 2-hydroxypropyl--cyclodextrin (HOP--CD),
we are able to administer SAHA in drinking water and dramat-
ically improve motor impairment in the R62 mouse model.
Methods
Drug Formulation. SAHA (Aton Pharma) was solubilized in 5
molar equivalents of HOP--CD (ICN) in water. In the main
trial, 0.67 g of SAHA was added to a solution of 18 g of
HOP--CD in 1 liter of water, heated until fully dissolved, and
rapidly cooled on ice to room temperature. This solution was
administered to the mice in place of drinking water and replaced
weekly. SAHA solutions of various concentrations were pre-
pared by maintaining the molar ratio between SAHA and
HOP--CD. Placebo was an equivalent concentration of HOP-
-CD without SAHA.
Animals. Affected mice were hemizygous R62 females (20)
[available from the Induced Mutant Resource, The Jackson
Laboratory, code B6CBA-TgN (HDexon1)62] bred and reared
in our colony by backcrossing R62 males to C57BL6  CBA
F1 females. Transgenic animals were identified before weaning
by PCR of tail-tip DNA, and CAG repeat size was determined
(26). Control mice were WT female littermates. Mice were
weaned into their treatment groups at 4 weeks of age. All animals
had unlimited access to rodent breeding chow (Special Diet
Services, Witham, U.K.) from a food hopper and placebo or drug
solution. From age 12 weeks, all animals were additionally given
mash consisting of powdered chow mixed with the drug solution
as given in the drinking bottle. The mice were subject to a 12-h
light (08:00–20:00), 12-h dark (20:00–08:00) cycle. Living con-
ditions and baseline characteristics of study groupings were
rigorously standardized.
Organotypic Slice Culture Assay. Organotypic hippocampal slice
cultures were established as described (27). SAHA in HOP-
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-CD solution was added to the culture medium from day 1 until
the termination of the experiment at concentrations from 0.025
to 250 M, and HOP--CD and media controls were included.
We established that HOP--CD has no effect on polyQ aggre-
gation over a 5-log concentration range (data not shown), and
therefore the HOP--CD concentration required to complex 250
M was used as the vehicle in this experiment. The medium was
changed twice weekly, and slices were fixed at weekly intervals
from 2 weeks in culture. The huntingtin aggregate load was
assessed by quantitative indirect immunofluorescence (27), and
results were analyzed by using the general linear model ANOVA
with false discovery rate correction (28).
Behavioral Analysis. Rotarod impairment was assessed on a Ugo
Basile 7650 accelerating Rotarod (Linton Instrumentation, Diss,
U.K.), modified as described (29). Animals (R62: n  13, WT:
n  12 per treatment group) were tested at 4 weeks of age to
establish their baseline performance and again at 8, 10, and 12
weeks of age. Grip strength was measured once per fortnight
(29), and animals were weighed weekly to the nearest 0.1 g.
Statistical analysis of grip strength used ANOVA on the mean
grip strength. Rotarod data were analyzed at each time point by
using repeated measures in a linear mixed effects model (in
S-plus).
Antibodies, Western Blotting, Histology, and Immunohistochemistry.
Antibodies were as follows: huntingtin exon 1 protein (S830)
(30); ubiquitin (DAKO); acetylated histone H2A (Lys-5) and
acetylated histone H2B (Serotec); and acetylated histone H3 and
acetylated histone H4 (Upstate Biotechnology, Lake Placid,
NY). Histones were isolated from whole brain, and Western
blots for histone acetylation (31) were as published. Brains for
histology and immunohistochemistry were frozen in isopentane
and stored at80°C until required, and 15-m sections were cut
by using a cryostat (Bright Instrument, Huntingdon, U.K.).
Immunohistochemistry was performed as described (27). Nissl
staining was carried out by standard protocols (32), with the
exception that frozen sections were postfixed in 4% paraformal-
dehyde for 30 min and washed in TBS (50 mM TrisHCl, pH
7.50.9% NaCl) before staining.
Real-Time RT-PCR Analysis. RNA was prepared from whole brain
by using the RNeasy mini kit (Qiagen, Crawley, U.K.) according
to the manufacturer’s recommendations. Real-time PCR was
performed as described (33) by using the ABI Prism 7700
(Perkin–Elmer-Applied Biosystems). R62 transgene primers
were: GCTGCACCGACCGTGAGT (forward), CAGGCTG-
CAGGGTTAC (reverse), and CAGCTCCCTGTCCCGGCGG
(probe). Abl primers were: CAAATCCAAGAAGGGGCTCTCT
(forward), TCGAGCTGCTTCGCTGAGA (reverse), and CCCT-
GCAGAGGCCAGTGGCATCT (probe).
Results
SAHA Crosses the Blood–Brain Barrier and Increases Histone Acetyla-
tion in Brain. Our initial experiments sought to determine whether
SAHA crosses the blood–brain barrier. SAHA is relatively
insoluble in aqueous solutions, and in previous mouse efficacy
studies (31), it had been administered at doses up to 100 mgkg
i.p. in 100% DMSO or orally in the diet (34). The parenteral
mode of administration was likely to be impractical in an efficacy
study that required daily dosing, as DMSO is not well tolerated
on repeated injection. Therefore, alternative vehicles for SAHA
delivery were investigated and we found that SAHA is capable
of forming a complex with HOP--CD with greatly enhanced
aqueous solubility.
Increased levels of histone acetylation resulting from i.p.
Fig. 1. SAHA crosses the blood–brain barrier and increases histone acetyla-
tion. Histones H2B and H4 are dramatically hyperacetylated 2 h post-s.c.
administration of the SAHA HOP--CD complex in both brain and spleen.
There is no difference in acetylation between genotypes.
Fig. 2. Dose escalation strategy for oral SAHA administration in WT mice.
(a) To determine the maximum dose of SAHA, which when complexed with
HOP--CD could be administered to WT mice in drinking water, a dose
escalation strategy was used (Table 1). Our initial intention was to assess the
tolerability of 2.67 gliter (400 mgkg) and 4 gliter (600 mgkg). (b) Doses of
2.67 gliter SAHA and above caused dramatic weight loss. On lowering the
dose from 3.33 gliter to 2 gliter (300 mgkg), the formulation was well
tolerated.
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injection of 50 mgkg SAHA are readily detected in tumor tissue
(31). To determine whether comparable levels of acetylation are
apparent in brain, either 100 mgkg or 200 mgkg SAHA in
HOP--CD was administered to WT and R62 mice by a single
s.c. injection, and brain and spleen samples were taken 2, 3, and
6 h after drug administration. For comparison, 100 mgkg
SAHA in either HOP--CD or DMSO was administered to WT
and R62 by single i.p. injection. We found no difference in the
degree of histone acetylation between untreated WT and R62
mice. Significant increases in histone acetylation could be de-
tected only on s.c. administration of 200 mgkg (Fig. 1). Ad-
ministration of SAHA dramatically increased acetylation of
histones H2B and H4 2 h postinjection (Fig. 1); this increase was
maintained at 3 h and had diminished by 6 h (data not shown).
With this regimen, increases in histone acetylation were similar
in the brain and spleen and comparable between WT and R62
mice. Therefore, SAHA is able to cross the blood–brain barrier
and mount a biological response.
SAHA Can Be Administered in Drinking Water. We had observed
increases in histone acetylation in brain tissue after s.c. admin-
istration of 200 mgkg SAHA in HOP--CD. However, at the
Fig. 3. Study design and outcome measures for the SAHA preclinical trial. (a) Comparison of the variation in age, weight, grip strength, and Rotarod
performance between treatment groups and before SAHA or placebo administration. (b) R62 mice treated with 0.67 gliter SAHA show a highly significant
improvement in Rotarod performance. Latency to fall at 8 weeks of age was 207 versus 144 s (P 0.003), at 10 weeks was 187 versus 113 s (P 0.0001), and at
12 weeks was 144 versus 72 s (P 0.0006). There was no significant difference in the performance of SAHA- and placebo-treated WT mice (P 0.28 at 8 weeks,
P  0.14 at 10 weeks, P  0.38 at 12 weeks). (c) Administration of SAHA does not improve mean grip strength in either WT or R62 mice. However, correction
for weight revealed a relative improvement in grip strength in the R62 mice treated with SAHA (P 0.012). (d) Both WT and R62 mice treated with SAHA failed
to gain weight to the same extent as compared with their littermates taking the placebo control. Also, we found no treatment-related difference in the
magnitude of weight loss of R62 mice compared with WT.
Table 1. Strategy used to establish dosing regime for SAHA
Dosage Genotype Treatment Route Duration Outcome
200 mgkg WT and R62 SAHA and placebo s.c. 5 days Irritation at injection site and death; study arm terminated
0.67 gliter WT and R62 SAHA and placebo Oral 3 weeks Mice survived; no significant weight loss
1.33 gliter WT and R62 SAHA and placebo Oral 3 weeks Mice survived; no significant weight loss
DE to 2 gliter WT SAHA and placebo Oral 3 weeks Mice survived; no significant weight loss
DE to 2 gliter R62 SAHA and placebo Oral 1 week Mice lost weight; death occurred; study arm terminated
DE to 2 gliter R62 Placebo Oral 1 week Mice survived; no significant weight loss; study arm terminated
DE to 2.67 gliter WT SAHA and placebo Oral 3 weeks Mice lost weight; study arm terminated
Summary of tolerability studies used to determine optimum dosing regime of SAHA. DE, dose escalation.
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concentration required to achieve SAHA dosages of 100–200
mgkg by injection, the cyclodextrin vehicle was viscous and
difficult to handle. Therefore, we aimed to administer 200 mgkg
SAHA in HOP--CD in drinking water. Assuming that a 20-g
mouse drinks 3 mlday (35), this corresponds to a dose of 1.33
gliter. Using a dose escalation strategy (Fig. 2a, Table 1), we
found that we could administer oral doses of up to 2 gliter in
WT mice for up to 3 weeks starting at 6–7 weeks of age without
significant weight loss or other adverse effects (Fig. 2b). How-
ever, application of this dosing regime to R62 mice resulted in
weight loss, and one mouse (of four) died within 1 week. R62
mice on the HOP--CD placebo concentration corresponding to
the 2 gliter SAHA dose suffered no adverse effects, and R62
mice receiving up to 1.33 gliter SAHA also showed no adverse
symptoms (data not shown).
We therefore initiated an eight-arm efficacy trial comprising
two drug (0.67 gliter and 1.33 gliter SAHA in HOP--CD) and
two placebo arms (the corresponding HOP--CD concentra-
tions) for WT and R62 mice. Drug administration commenced
at 30 days of age after an initial testing week, which was used to
sort the mice into well-matched treatment groups (Fig. 3a).
Similarly, the CAG repeat size of the R62 mice was well
matched at 200 4 (SD). Unexpectedly, given the results of our
pilot studies, both WT and R62 mice on 1.33 gliter SAHA
failed to gain weight, and after 2 weeks, weighed20% less than
mice on the corresponding placebo (data not shown). In addi-
tion, 212 WT and 213 R62 mice in this study arm died at 6
weeks of age. Therefore, we terminated the 1.33 gliter SAHA
and placebo arms of the experiment and proceeded only with the
0.67 gliter and corresponding placebo groups.
SAHA Improves Motor Impairment in R62 Mice. The effect of SAHA
administration on the R62 phenotype was assessed by Rotarod
analysis of motor impairment, grip strength, and failure to gain
weight. R62 mice treated with 0.67 gliter SAHA showed a
strong and consistent improvement in Rotarod performance as
compared with those on placebo (Fig. 3b). The regression of
mean latency times at weeks 8, 10, and 12 showed a highly
significant difference between R62 mice on placebo and R62
mice on SAHA (P  0.0009). There were no significant differ-
ences in performance of SAHA-treated WT mice compared
with WT mice on placebo (Fig. 3b). The performance of both
WT and R62 mice on placebo was consistent with findings from
recent experiments by using the same protocol at all time points
(R62: 8 weeks, 141–148 s; 12 weeks, 55–77 s) (WT: 8 weeks,
250–288 s; 12 weeks, 230–262 s). In contrast, the mean perfor-
mance of R62 mice on SAHA from 8 weeks was well above the
upper limit from all previous tests.
We found no significant difference in mean grip strength (Fig.
3c) between treated and placebo mice of either genotype at any
age. WT mice in both treatment arms performed significantly
better than R62 mice at 12 weeks of age (placebo: P  105;
SAHA, P  0.02). SAHA did not prevent the failure of R62
mice to gain weight (Fig. 3d). R62 mice were20% lighter than
WT mice at 13 weeks in both treatment groups. However, both
WT and R62 mice treated with SAHA failed to gain weight to
the same extent as their littermates taking the placebo control
(both 18% at 13 weeks compared with appropriate placebo
group). If this additional weight loss is caused by marginal
toxicity of SAHA, it seems that there is no interaction with
genotype: WT and R62 mice are equally affected. By regression
analysis, weight was a significant positive predictor of mean grip
strength in R62 (P  0.015), but not in WT (P  0.229) mice
at 12 weeks of age. Entering both weight and treatment received
into a multiple regression model revealed an improvement in
grip strength at 12 weeks in R62 (P 0.012) but not in WT (P
0.810) mice treated with SAHA.
Effects of SAHA on Gross and Cellular Brain Morphology. Examina-
tion of Nissl-stained brain sections revealed no overt difference
in gross morphology between WT and R62 mice treated with
either SAHA or placebo (Fig. 4a). Although the R62 mean
brain weight was significantly less than WT (Student’s t test:
R62, 0.396 g; WT, 0.447 g; P  0.01), there was no difference
by regression analysis between mice treated with SAHA or
placebo (P  0.777). Similarly, there was no correlation with
body weight within each genotype (P  0.243).
Examination of the Nissl-stained sections under higher power
revealed cellular atrophy in the R62 striatum as compared with
WT (Fig. 4b) as documented (22). Treatment of R62 mice with
SAHA resulted in Nissl staining more closely resembling that in
WT mice.
SAHA Does Not Inhibit PolyQ Aggregation. To rule out that SAHA
might exert its effects through the inhibition of polyQ aggrega-
tion, its ability to act as an aggregation inhibitor was tested in an
organotypic slice culture assay (27). We have developed this
technique to bridge the gap between wholly in vitro aggregation
assays and preclinical trials and allow us to quantify aggregate
formation in a system in which aggregates form at the same rate
and in the same sequence as they do in vivo. Hippocampal slices
were established from R62 neonates at P7 and cultured in the
presence of SAHA complexed with HOP--CD at concentra-
tions ranging from 0.025 to 250 M over a period of 4 weeks.
Fig. 4. Effect of SAHA on gross and cellular brain morphology. Frozen brain
sections were cut from mice at 13 weeks of age, between Bregma 0 and 0.5 mm
in the region of 0.26 mm and stained for Nissl substance with cresyl violet. (a)
There is no marked change in gross morphology between R62 and WT mice
in either treatment group. (b) Cellular atrophy is apparent in Nissl-stained
sections from R62 brains. Treatment of R62 mice with SAHA resulted in Nissl
staining more closely resembling that seen in WT mice.
2044  www.pnas.orgcgidoi10.1073pnas.0437870100 Hockly et al.
Concentrations of 25 and 250 M proved toxic. After 3 and 4
weeks there was no difference in the aggregate load between
slices cultured in 0.025, 0.25, or 2.5 M SAHA as compared with
vehicle control (Fig. 5a). By a less quantitative immunohisto-
chemical approach, no treatment-related differences in aggre-
gate load were detected by using either antihuntingtin or antiu-
biquitin antibodies to immunoprobe sections of postmortem
brains from R62 mice (Fig. 5b.).
SAHA Does Not Down-Regulate the R62 Transgene. To ensure that
SAHA is not acting directly on the transgene promoter to
down-regulate the R62 transgene, RNA was prepared from the
brains of R62 mice that had been treated with either 0.67 gliter
SAHA or placebo for 17 days. Experiments were performed in
triplicate, and the number of real-time PCR products was
determined for the R62 transgene by using the c-abl oncogene
as control (Fig. 5c). There is no difference in the level of
expression of the R62 transgene (P  0.92) or c-abl (P  0.69)
between SAHA- and placebo-treated mice.
Discussion
HDAC inhibitors have been shown to reduce polyQ toxicity in
a Drosophila model of HD (11). We now show that the potent
HDAC inhibitor, SAHA, dramatically improves Rotarod per-
formance in the R62 HD mouse model. R62 mice treated with
0.67 gliter SAHA demonstrated a significant improvement at 8
weeks of age after only 3 weeks of drug administration. At 12
weeks, the R62 mice taking SAHA were performing as well as
the placebo group did at 8 weeks, indicating a delay by as much
as 1 month in the decline in Rotarod performance. These results
are yet more impressive given that our mice were housed in
environmentally enriched conditions, which alone improved the
Rotarod performance of R62 mice by 40% of the difference
between R62 and WT (29). Therefore, drugs tested in our
preclinical trials must cause significant additional improvement
to be registered as effective. Our demonstration that SAHA
treatment in part redresses the loss of striatal Nissl staining
suggests that this may represent a neuropathological correlate of
motor impairment.
SAHA is a small hydrophobic molecule and its relative
insolubility in aqueous solution posed considerable difficulties.
To combat this, we determined that SAHA is capable of forming
a complex with HOP--CD with greatly enhanced aqueous
solubility. Cyclodextrins are doughnut-shaped molecules con-
sisting of six (), seven (), or eight () glucose units linked by
-1,4 glycosidic bonds with their hydrophobic faces innermost.
Small hydrophobic molecules can enter the central cavity to form
a complex with the cyclodextrin. Because the hydrophilic sur-
faces of the cyclodextrins face outward, aqueous solubility is
imparted on the complexes. Complexation with cyclodextrins
can have additional benefits. These include a reduction in drug
toxicity and irritation at the site of administration, masking of
unpleasant tastes, and alteration of the pharmacokinetic profile
of a drug, often increasing the half-life. HOP--CD is a nontoxic
semisynthetic cyclodextrin, which is widely used in vitro and
in vivo as a drug carrier in both enteral and parenteral formula-
tions (36).
SAHA did not ameliorate the failure of R62 mice to gain
weight, possibly reflecting its narrow therapeutic window with
beneficial effects being masked by its toxicity. When SAHA
administration was initiated at 30 days, doses 1.33 gliter were
toxic to both WT and R62 mice. Adverse effects were also seen
in both WT and R62 mice at the effective dose of 0.67 gliter,
with mice failing to gain weight at the same rate as placebo-
treated mice. However, despite this inherent toxicity, no R62
mice or WT mice died before the termination of the experiments
at 13 weeks, and maintenance of grip strength in SAHA-treated
R62 mice may indicate a sparing of muscle atrophy.
This study corroborates the use of HDAC inhibitors as
therapeutic compounds for HD. Our demonstration that SAHA
administration increases histone acetylation supports the hy-
pothesis that it acts by redressing transcriptional repression.
Although our results demonstrate that the identification of
potential therapeutic compounds in Drosophila models can
translate to preclinical mouse trials, we would caution against
Fig. 5. SAHA does not inhibit polyQ aggregation or decrease transgene protein levels. (a) Quantification of aggregate load in hippocampal slice cultures that
have been incubated in the presence of SAHA or HOP--CD for 4 weeks. SAHA has no effect on aggregate count, aggregate fluorescence intensity, or aggregate
area. Error bars SD. (b) Immunodetection of polyQ aggregates (arrow) using antibodies raised against huntingtin (S830) and ubiquitin in postmortem brains
from R62 mice at 13 weeks of age that had been administered SAHA or placebo for 8 weeks (age 13 weeks). (c) Real-time PCR to determine the level of expression
of the R62 transgene and c-abl oncogene. R62 mice (10–11 weeks) had been treated with 0.67 gliter SAHA (n  7) or placebo (n  7) for 17 days.
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proceeding too rapidly to clinical trials. Demonstration of effi-
cacy with SAHA is particularly encouraging as this drug is 103
fold more potent than the butyrate class of HDAC inhibitors [on
a molar basis as an inhibitor of HDAC activity (15)] that are also
under consideration. However, novel hydroxamic acid deriva-
tives with enhanced activity as potential HD therapeutics also
should be assessed.
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